Milbeguard Duo 16 mg / 40 mg film-coated tablets for cats

Nazione: Irlanda

Lingua: inglese

Fonte: HPRA (Health Products Regulatory Authority)

Principio attivo:

Milbemycin oxime; Praziquantel

Commercializzato da:

Ceva Santé Animale

Codice ATC:

QP54AB51

INN (Nome Internazionale):

Milbemycin oxime; Praziquantel

Forma farmaceutica:

Film-coated tablet

Tipo di ricetta:

POM: Prescription Only Medicine as defined in relevant national legislation

Area terapeutica:

milbemycin oxime, combinations

Data dell'autorizzazione:

2024-01-19

Scheda tecnica

1
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Milbeguard Duo 16 mg / 40 mg film-coated tablets for cats
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCES:
Milbemycin oxime
16 mg
Praziquantel
40 mg
EXCIPIENTS:
QUALITATIVE
COMPOSITION OF EXCIPIENTS AND
OTHER CONSTITUENTS
Core:
Povidone
Croscarmellose sodium
Chicken flavour*
Lactose monohydrate
Cellulose microcrystalline
Silica, colloidal anhydrous
Magnesium stearate
Coat:
Polyvinyl alcohol (E1203)
Macrogol (E1521)
Talc (E553b)
Ponceau 4R (E124)
Sunset yellow (E110)
Titanium dioxide (E171)
_*Artificial origin _
Oblong tablet, red to reddish brown, scored on one side. The tablet
can be divided into two equal parts.
3.
CLINICAL INFORMATION
3.1
TARGET SPECIES
Cats weighing at least 2 kg
3.2
INDICATIONS FOR USE FOR EACH TARGET SPECIES
In cats: treatment of mixed infections by immature and adult cestodes
and nematodes of the following
species:
- Cestodes:
_Dipylidium caninum _
2
_Taenia _
spp
_. _
_Echinococcus multilocularis _
- Nematodes:
_Ancylostoma tubaeforme _
_Toxocara cati _
Prevention of heartworm disease (
_Dirofilaria immitis_
) if concomitant treatment against cestodes is
indicated.
3.3
CONTRAINDICATIONS
Do not use in cats weighing less than 2 kg.
Do not use in cases of hypersensitivity to the active substances or to
any of the excipients.
3.4
SPECIAL WARNINGS
Unnecessary use of antiparasitics or use deviating from the
instructions given in the SPC may increase
the resistance selection pressure and lead to reduced efficacy. The
decision to use the product should be
based on confirmation of the parasitic species and burden, or of the
risk of infection based on its
epidemiological features, for each individual animal.
It is recommended to treat all the animals living in the same
household concomitantly.
When infection with the cestode
_D. caninum_
has been confirmed, concomitant treatment against
intermediate hosts, such as fleas and lice, should be discussed with a
veterinarian to prevent re-infection.
Parasite resistance to a